Private Harbour Investment Management & Counsel LLC increased its position in shares of Zoetis Inc (NYSE:ZTS) by 0.7% during the 1st quarter, HoldingsChannel reports. The firm owned 19,268 shares of the company’s stock after buying an additional 135 shares during the quarter. Zoetis accounts for 2.0% of Private Harbour Investment Management & Counsel LLC’s investment portfolio, making the stock its 16th biggest holding. Private Harbour Investment Management & Counsel LLC’s holdings in Zoetis were worth $1,940,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently made changes to their positions in the stock. Nordea Investment Management AB grew its stake in shares of Zoetis by 8.5% in the third quarter. Nordea Investment Management AB now owns 98,738 shares of the company’s stock valued at $9,041,000 after buying an additional 7,737 shares in the last quarter. Vanguard Group Inc grew its stake in shares of Zoetis by 0.8% in the third quarter. Vanguard Group Inc now owns 35,947,496 shares of the company’s stock valued at $3,291,353,000 after buying an additional 293,614 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Zoetis in the fourth quarter valued at $370,000. Steward Partners Investment Advisory LLC grew its stake in shares of Zoetis by 53.3% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 8,075 shares of the company’s stock valued at $690,000 after buying an additional 2,808 shares in the last quarter. Finally, BKD Wealth Advisors LLC grew its stake in shares of Zoetis by 8.9% in the fourth quarter. BKD Wealth Advisors LLC now owns 2,741 shares of the company’s stock valued at $234,000 after buying an additional 224 shares in the last quarter. 90.78% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts have recently weighed in on ZTS shares. Zacks Investment Research cut Zoetis from a “buy” rating to a “hold” rating in a research note on Monday, May 6th. Gabelli cut Zoetis from a “buy” rating to a “hold” rating and set a $108.00 target price for the company. in a research note on Thursday, May 2nd. They noted that the move was a valuation call. Credit Suisse Group boosted their target price on Zoetis from $102.00 to $112.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 2nd. UBS Group started coverage on Zoetis in a research note on Wednesday, January 23rd. They set a “neutral” rating and a $86.00 target price for the company. Finally, SunTrust Banks started coverage on Zoetis in a research note on Tuesday, March 19th. They set a “hold” rating and a $100.00 target price for the company. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $103.15.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 2nd. The company reported $0.88 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.09. Zoetis had a return on equity of 73.66% and a net margin of 23.47%. The firm had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.45 billion. During the same period in the previous year, the firm posted $0.75 EPS. Zoetis’s revenue for the quarter was up 6.5% on a year-over-year basis. As a group, research analysts forecast that Zoetis Inc will post 3.48 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 19th will be issued a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is 21.09%.
In other Zoetis news, EVP Clinton A. Jr. Lewis sold 6,123 shares of Zoetis stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $101.90, for a total transaction of $623,933.70. Following the completion of the sale, the executive vice president now directly owns 51,926 shares of the company’s stock, valued at approximately $5,291,259.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Catherine A. Knupp sold 32,767 shares of Zoetis stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $95.80, for a total value of $3,139,078.60. Following the sale, the insider now directly owns 82,820 shares of the company’s stock, valued at $7,934,156. The disclosure for this sale can be found here. Insiders have sold a total of 439,784 shares of company stock valued at $41,891,618 over the last ninety days. 0.29% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This news story was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/05/17/zoetis-inc-zts-stake-raised-by-private-harbour-investment-management-counsel-llc.html.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: What is the Stochastic Momentum Index (SMI)?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.